Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 2, 2021
- Pharmaceutical Technology, August 2021 Issue
- Volume 45
- Issue 8
Grouping Products and Equipment for a Worst-Case Cleaning Validation Study
Author(s)Richard J. Forsyth
A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.
Advertisement
Peer-Reviewed
Submitted: December 1, 2020
Accepted: February 5, 2021
Abstract
Cleaning validation requires a significant effort to design a strategic and effective program that is defendable with regulatory agencies. Of primary concern is what to validate. A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.
About the author
Richard Forsyth is a Principal Consultant with Forsyth Pharmaceutical Consulting.
Article Details
Pharmaceutical Technology
Vol. 45, No. 8
August 2021
Pages: 44–51
Citation
When referring to this article, please cite it as R. Forsyth, "Grouping Products and Equipment for a Worst-Case Cleaning Validation Study," Pharmaceutical Technology 45 (8) 2021.
Articles in this issue
about 5 years ago
Putting the Patient at the Heart of Dosage Form Designabout 5 years ago
A Digital Supply Chain Helps Ensure API Qualityabout 5 years ago
Serialization: Reducing Counterfeit Drugs and Increasing Salesabout 5 years ago
Designing Incubators for Cell Therapy Manufacturingabout 5 years ago
Implementing Data Integrity Compliance in a GLP Test Facilityabout 5 years ago
Developing the Best Formulation Partnershipabout 5 years ago
Working Towards Zero Emissionsabout 5 years ago
FDA Prioritizes Vaccine Review and Process Improvementsabout 5 years ago
Drug Pricing Scrutiny Increases in EuropeAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement